top of page

FDA Wrote the Playbook for the Next Outbreak Test. The Evidence Bar Is More Specific Than Most Teams Expect.

Writer: Lexim AI
Lexim AI
4 days ago
6 min read

On November 10, CDRH finalized Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency (document GUI00007020; Federal Register notice 91 FR 72541; docket FDA-2024-D-2707). It finalizes a January 2025 draft and ties into a companion template for pre-EUA and EUA submissions. The Federal Register notice says the work answers recommendations from reviews of the pandemic response that FDA laid out in advance on how diagnostic tests for emerging pathogens should be validated during a declared emergency.

The guidance is non-binding and applies only in a narrow circumstance: a public health emergency declaration under section 564 of the FD&C Act. But it is the most concrete statement FDA has published about what evidence it will look for first, when specimens are scarce and time is short. For any company that builds infectious disease diagnostics, it is also a planning document for the weeks before an outbreak, when the most important work gets done.


What it covers, and which standard applies

The guidance addresses diagnostic IVDs as defined in 21 CFR 809.3 that detect emerging pathogens to aid diagnosis of serious or life-threatening infectious disease, including tests for screening people without symptoms and home-use tests. It also covers home specimen collection kits and certain software used with diagnostic tests. Serology, antibody, and other adaptive immune response tests are outside its scope.

It applies to three situations: pre-EUA submissions, EUA requests, and tests offered under an applicable enforcement discretion policy. The timing matters. A company can submit a pre-EUA before a declaration exists, which is the point of the exercise. An EUA request, by contrast, requires a current applicable declaration.

The legal standard is the other thing to keep in mind. An EUA rests on the statutory "may be effective" standard in section 564(c)(2)(A), which is different from the effectiveness standards for clearance and approval under sections 513 and 515. The guidance's recommendations are calibrated to that lower, emergency-specific bar, and FDA says it has focused them on the most important and least burdensome information to collect during a declared emergency. Evidence that would satisfy a 510(k) is not the target here, and evidence collected for an EUA does not automatically carry over to a later marketing submission.


Where the specimens come from

Clinical performance is hardest for outbreak testing because the infected patients and reference methods you need are least available when you need them most. The guidance sets out a hierarchy. FDA prefers natural clinical specimens from a prospective study. Early in an outbreak, archived specimens may be a reasonable substitute. If neither is available, FDA may accept contrived samples, and synthetic material may be acceptable when pathogen stocks are not available. If FDA authorizes a test on contrived data, it would likely expect a follow-up study using natural specimens once that becomes feasible.

For sizing, the guidance gives a typical example rather than a requirement: for an established, high-sensitivity viral nucleic acid test where clinical specimens and comparators are generally available, at least 30 positive and 30 negative specimens. Results are generally reported as positive percent agreement (PPA) and negative percent agreement (NPA) against a highly sensitive comparator, with 95% Wilson score confidence intervals.

Two terms are worth unpacking. PPA and NPA are used instead of sensitivity and specificity because the comparator is itself imperfect, so the numbers describe agreement with the comparator, not the truth. And the Wilson score interval is a way of expressing uncertainty that behaves better than the simple textbook formula when samples are small, or results sit near 0% or 100%, which is exactly the situation in an early outbreak. The practical point is that a 30-positive study produces wide intervals, so FDA is asking for transparency about the uncertainty, not precision that doesn't yet exist.

For studies that involve specimens from people, the guidance notes that an IRB may waive or alter informed consent for some minimal-risk investigations under 21 CFR 50.22, and separately points to FDA's policy on certain leftover specimens that cannot be individually identified.


Analytical validation: the numbers

The analytical recommendations are more prescriptive, and several are precise enough to build a protocol from.

Study

What FDA recommends

Limit of detection (LoD)

Preliminary range-finding with 2- to 3-fold dilutions (3 replicates per level), then at least 20 replicates at the preliminary LoD. The confirmed LoD is the lowest concentration at which at least 95% of replicates are positive, for example 19 of 20. FDA advises against simulated matrix or recombinant antigen for LoD studies.

Inclusivity and variants

In silico alignment (100% nucleotide identity for molecular tests, or a risk assessment when mismatches occur with a significant number of published sequences), with wet testing for circulating variants when available. Re-evaluate monthly for clinically significant mutations, and run a risk analysis for any greater than 3-fold reduction in analytical sensitivity, including whether the combined effect pushes clinical performance below FDA's recommendations.

Specimen stability

If applicable, CDC specifications cover your storage and transport conditions, additional data are likely unnecessary. Otherwise, test live or inactivated pathogen spiked into negative clinical matrix around the LoD, plus at least 10 negative specimens.

The LoD definition deserves a second look. Twenty replicates with 19 positive gives a point estimate of 95%, but with so few replicates the true detection rate consistent with that result spans a wide range, roughly three-quarters to nearly 100% at 95% confidence. The LoD is an operational definition that lets two studies be compared, not a proof that the test detects 95% of samples at that level. That is one reason the guidance pairs it with variant monitoring and a later natural-specimen study.

The monthly inclusivity recommendation is the newest operational burden. A pathogen that mutates can quietly erode a test's sensitivity after authorization, and FDA's answer is a standing, scheduled review with a defined trigger (the 3-fold threshold) rather than an ad hoc response.


Change protocols replace the draft's PCCP language

The draft used the term PCCP, but the final guidance renamed the concept a Change Protocol because predetermined change control plans apply to marketing submissions, not EUAs. The idea is the same: a manufacturer can propose, in the initial EUA request, a protocol for future changes within the test's intended use, such as adding an instrument or a collection device. A change made under a protocol that FDA reviewed and included in the authorization is considered covered by that authorization, and FDA generally specifies implementation requirements in a condition of authorization. In an outbreak, when an authorized test needs a second instrument platform quickly, having an agreed validation plan in advance can save weeks.


Home use and point-of-care testing

For home-collection kits, over-the-counter tests, and point-of-care tests intended for CLIA-waived settings, the guidance adds human-factors expectations. It recommends quick reference instructions limited to one or two pages, written at no higher than a 7th-grade reading level, with pictures and diagrams, supported by usability, comprehension, and hazard-based flex studies.

For point-of-care tests, it describes a near-cutoff evaluation at one or two U.S. sites with four to six operators who have no laboratory training and represent the intended users. Each site tests 10 contrived specimens near the LoD (for example, within 3-fold) and 10 negative specimens, each operator tests at least 3 positives and 3 negatives, and the target is at least 95% positive and negative agreement, or a re-evaluation of the LoD.


What to do before the next declaration

Because the guidance is only useful if the groundwork exists before an emergency, the practical steps are about preparation:

  • Write the validation plan now, using the specimen hierarchy: what you would collect first, what you would substitute, and what the follow-up natural-specimen study would look like.

  • Identify a sensitive comparator with performance data for your intended specimen type, since PPA and NPA depend on it.

  • Decide which foreseeable changes belong in a Change Protocol, such as additional instruments, collection devices, or sample types, and document the validation and acceptance criteria for each.

  • Assign an owner for monthly variant review, with the 3-fold sensitivity trigger written into a procedure.

  • Use the pre-EUA template to test the plan with FDA before a declaration, and confirm what is covered by a general template versus what needs a sponsor-specific discussion.

  • For home and point-of-care products, plan the instructions and the lay-operator study early, because human-factors work is slow to improvise.


The guidance will not answer every question about a future outbreak, and its recommendations are explicitly flexible across outbreak stages. But it replaces a good deal of guesswork with a checklist, and the companies that have their plan in place before the declaration will be the ones that submit first.


Sources: FDA, Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency, final guidance GUI00007020 (November 10, 2026); Federal Register, notice of availability, 91 FR 72541 (docket FDA-2024-D-2707); FDA, General IVD EUA/Pre-EUA Template; Pure Global, FDA Finalizes Section 564 Emergency IVD Validation Guidance (November 15, 2026), for section locators and the comparison with the January 2025 draft.


Comments


bottom of page